A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...

Only men with prostate tumors of the luminal B subtype benefited from adding apalutamide to salvage radiation in the phase 2 ...

At ASTRO, Artera presented clinical validation data on its prostate cancer test in an Asian population,and showed how the test may complement gene expression-based approaches.

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate ...

Dr. Sutera opened his talk by outlining that he would divide his presentation into three parts: first, defining MMAI; second, discussing its application in oligometastatic prostate cancer; and third, ...

The core foundation of precision medicine, and in turn, precision oncology, is a personalized approach to treatment that focuses on targeting specific molecular features that impact how cancer cells ...

Neighborhood disadvantage is associated with greater expression of stress-related genes that are linked to more aggressive prostate cancer. Men from disadvantaged neighborhoods have higher expression ...

68Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study.

Researchers found that analyzing certain chemokine levels may help explain racial disparities in prostate cancer lethality, and that neutralizing such chemokines could potentially benefit prostate ...